title: This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis.
authors.affiliation: Centre for Rheumatology, Department of Medicine, University College of London, London, UK. clgorman@btopenworld.com
authors.forename: C
authors.initials: C
authors.lastname: Gorman
authors.forename: A
authors.initials: A
authors.lastname: Bhatia
authors.forename: A
authors.initials: A
authors.lastname: Rahman
mesh_terms: D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007275:Injections, Intravenous; D008181:Lupus Nephritis / Q000188:drug therapy*; D020551:Pulse Therapy, Drug; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide